Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.

Long GV, Saw RPM, Lo S, Nieweg OE, Shannon KF, Gonzalez M, Guminski A, Lee JH, Lee H, Ferguson PM, Rawson RV, Wilmott JS, Thompson JF, Kefford RF, Ch'ng S, Stretch JR, Emmett L, Kapoor R, Rizos H, Spillane AJ, Scolyer RA, Menzies AM.

Lancet Oncol. 2019 Jul;20(7):961-971. doi: 10.1016/S1470-2045(19)30331-6. Epub 2019 Jun 3.

PMID:
31171444
2.

Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure.

Cust AE, Drummond M, Bishop DT, Azizi L, Schmid H, Jenkins MA, Hopper JL, Armstrong BK, Aitken JF, Kefford RF, Giles GG, Demenais F, Goldstein AM, Barrett JH, Kanetsky PA, Elder DE, Mann GJ, Newton-Bishop JA.

J Eur Acad Dermatol Venereol. 2019 May 13. doi: 10.1111/jdv.15680. [Epub ahead of print]

3.

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.

Lee JH, Saw RP, Thompson JF, Lo S, Spillane AJ, Shannon KF, Stretch JR, Howle J, Menzies AM, Carlino MS, Kefford RF, Long GV, Scolyer RA, Rizos H.

Ann Oncol. 2019 May 1;30(5):815-822. doi: 10.1093/annonc/mdz075.

4.

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.

Pires da Silva I, Wang KYX, Wilmott JS, Holst J, Carlino MS, Park JJ, Quek C, Wongchenko M, Yan Y, Mann G, Johnson DB, McQuade JL, Rai R, Kefford RF, Rizos H, Scolyer RA, Yang JYH, Long GV, Menzies AM.

Clin Cancer Res. 2019 Feb 15;25(4):1272-1279. doi: 10.1158/1078-0432.CCR-18-1680. Epub 2019 Jan 10.

PMID:
30630828
5.

Evaluation of commercial kits for purification of circulating free DNA.

Diefenbach RJ, Lee JH, Kefford RF, Rizos H.

Cancer Genet. 2018 Dec;228-229:21-27. doi: 10.1016/j.cancergen.2018.08.005. Epub 2018 Aug 29.

PMID:
30553469
6.

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy.

Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, Breen EJ, Yang JYH, Ghazanfar S, Kefford RF, Scolyer RA, Long GV, Rizos H.

Clin Cancer Res. 2019 Mar 1;25(5):1557-1563. doi: 10.1158/1078-0432.CCR-18-2795. Epub 2018 Nov 8.

PMID:
30409824
7.

bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arrays.

Wang KYX, Menzies AM, Silva IP, Wilmott JS, Yan Y, Wongchenko M, Kefford RF, Scolyer RA, Long GV, Tarr G, Mueller S, Yang JYH.

Bioinformatics. 2019 Apr 15;35(8):1350-1357. doi: 10.1093/bioinformatics/bty783.

PMID:
30215668
8.

Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility.

Wilmott JS, Johansson PA, Newell F, Waddell N, Ferguson P, Quek C, Patch AM, Nones K, Shang P, Pritchard AL, Kazakoff S, Holmes O, Leonard C, Wood S, Xu Q, Saw RPM, Spillane AJ, Stretch JR, Shannon KF, Kefford RF, Menzies AM, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA.

Int J Cancer. 2019 Mar 1;144(5):1049-1060. doi: 10.1002/ijc.31791. Epub 2018 Nov 21.

PMID:
30178487
9.

Interferon Signaling Is Frequently Downregulated in Melanoma.

Alavi S, Stewart AJ, Kefford RF, Lim SY, Shklovskaya E, Rizos H.

Front Immunol. 2018 Jun 21;9:1414. doi: 10.3389/fimmu.2018.01414. eCollection 2018.

10.

Oncogenic signaling in uveal melanoma.

Park JJ, Diefenbach RJ, Joshua AM, Kefford RF, Carlino MS, Rizos H.

Pigment Cell Melanoma Res. 2018 Nov;31(6):661-672. doi: 10.1111/pcmr.12708. Epub 2018 May 23. Review.

PMID:
29738114
11.

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.

Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford RF, Rizos H, Carlino MS.

JAMA Oncol. 2018 May 1;4(5):717-721. doi: 10.1001/jamaoncol.2017.5332.

12.

Liquid biomarkers in melanoma: detection and discovery.

Lim SY, Lee JH, Diefenbach RJ, Kefford RF, Rizos H.

Mol Cancer. 2018 Jan 17;17(1):8. doi: 10.1186/s12943-018-0757-5. Review.

13.

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.

Lee JHJ, Lyle M, Menzies AM, Chan MMK, Lo S, Clements A, Carlino MS, Kefford RF, Long GV.

Pigment Cell Melanoma Res. 2018 May;31(3):404-410. doi: 10.1111/pcmr.12675. Epub 2017 Dec 7.

PMID:
29171176
14.

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients.

Lim SY, Lee JH, Welsh SJ, Ahn SB, Breen E, Khan A, Carlino MS, Menzies AM, Kefford RF, Scolyer RA, Long GV, Rizos H.

Biomark Res. 2017 Nov 10;5:32. doi: 10.1186/s40364-017-0112-9. eCollection 2017.

15.

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.

Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, Kefford RF, Howle JR, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, Rizos H.

Clin Cancer Res. 2017 Oct 15;23(20):6054-6061. doi: 10.1158/1078-0432.CCR-16-1688. Epub 2017 Jul 19.

16.

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.

Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan R, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart DD, Moutouh-de Parseval L, Demuth T, Dummer R.

Clin Cancer Res. 2017 Sep 15;23(18):5339-5348. doi: 10.1158/1078-0432.CCR-16-2923. Epub 2017 Jun 13.

17.

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS.

Br J Cancer. 2017 Jun 6;116(12):1558-1563. doi: 10.1038/bjc.2017.142. Epub 2017 May 18.

18.

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, Liniker E, Kong BY, Cooper AJ, Howle JR, Saw RPM, Jakrot V, Lo S, Thompson JF, Carlino MS, Kefford RF, Long GV, Scolyer RA.

Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16.

19.

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing.

Pupo GM, Boyd SC, Fung C, Carlino MS, Menzies AM, Pedersen B, Johansson P, Hayward NK, Kefford RF, Scolyer RA, Long GV, Rizos H.

Biomark Res. 2017 May 11;5:17. doi: 10.1186/s40364-017-0098-3. eCollection 2017.

20.

Whole-genome landscapes of major melanoma subtypes.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ.

Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3.

PMID:
28467829
21.

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H.

Ann Oncol. 2017 May 1;28(5):1130-1136. doi: 10.1093/annonc/mdx026.

PMID:
28327969
22.

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM.

J Clin Oncol. 2017 Mar 10;35(8):885-892. doi: 10.1200/JCO.2016.70.2951. Epub 2017 Jan 30.

23.

Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis.

Park JJ, Boddy AV, Liu X, Harris D, Lee V, Kefford RF, Carlino MS.

Pigment Cell Melanoma Res. 2017 Jan;30(1):68-71. doi: 10.1111/pcmr.12557.

PMID:
27863085
24.

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma.

Liniker E, Menzies AM, Kong BY, Cooper A, Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, Carlino MS, Hong A, Long GV.

Oncoimmunology. 2016 Aug 19;5(9):e1214788. eCollection 2016.

25.

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

Carlino MS, Vanella V, Girgis C, Giannarelli D, Guminski A, Festino L, Kefford RF, Menzies AM, Long GV, Ascierto PA.

Br J Cancer. 2016 Nov 22;115(11):1280-1284. doi: 10.1038/bjc.2016.321. Epub 2016 Oct 6.

26.

Sentinel node biopsy for melanoma: The medical oncology perspective.

Menzies AM, Atkinson VG, Brown MP, Carlino MS, Cebon J, Guminski A, Kefford RF, Long GV, McArthur G, McNeil CM, Millward M, Sandhu S.

Aust Fam Physician. 2015 Dec;44(12):875-6. No abstract available.

PMID:
27505912
27.

Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy.

Kong BY, Menzies AM, Saunders CA, Liniker E, Ramanujam S, Guminski A, Kefford RF, Long GV, Carlino MS.

Pigment Cell Melanoma Res. 2016 Sep;29(5):572-7. doi: 10.1111/pcmr.12503. Epub 2016 Aug 4.

PMID:
27333363
28.

The molecular profile of metastatic melanoma in Australia.

Lyle M, Haydu LE, Menzies AM, Thompson JF, Saw RP, Spillane AJ, Kefford RF, Mann GJ, Cooper WA, Yu B, Scolyer RA, O'Toole SA, Long GV.

Pathology. 2016 Feb;48(2):188-93. doi: 10.1016/j.pathol.2015.12.008. Epub 2016 Jan 18.

PMID:
27020391
29.

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT.

J Clin Oncol. 2016 Mar 10;34(8):871-8. doi: 10.1200/JCO.2015.62.9345. Epub 2016 Jan 25. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):355.

PMID:
26811525
30.

Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.

Kong BY, Micklethwaite KP, Swaminathan S, Kefford RF, Carlino MS.

Melanoma Res. 2016 Apr;26(2):202-4. doi: 10.1097/CMR.0000000000000232.

PMID:
26795275
31.

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D.

Eur J Cancer. 2015 Dec;51(18):2792-9. doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19.

32.

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

Carlino MS, Long GV, Kefford RF, Rizos H.

Crit Rev Oncol Hematol. 2015 Dec;96(3):385-98. doi: 10.1016/j.critrevonc.2015.08.021. Epub 2015 Aug 28. Review.

PMID:
26358420
33.

Immune checkpoint inhibitors in melanoma.

Cooper AJ, Carlino MS, Kefford RF.

Melanoma Manag. 2015 Aug;2(3):267-284. doi: 10.2217/mmt.15.17. Epub 2015 Aug 10. Review.

34.

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.

Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MM, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV.

Cancer. 2015 Nov 1;121(21):3826-35. doi: 10.1002/cncr.29586. Epub 2015 Jul 28.

35.

Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.

Lam T, Chan MM, Sweeting AN, De Sousa SM, Clements A, Carlino MS, Long GV, Tonks K, Chua E, Kefford RF, Chipps DR.

Intern Med J. 2015 Oct;45(10):1066-73. doi: 10.1111/imj.12819. Erratum in: Intern Med J. 2015 Dec;45(12):1318.

PMID:
26010858
36.

Expanded access programmes: patient interests versus clinical trial integrity.

Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM.

Lancet Oncol. 2015 Jan;16(1):15-7. doi: 10.1016/S1470-2045(14)71161-1. Epub 2014 Dec 29. No abstract available.

PMID:
25638540
37.

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, Scolyer RA.

Clin Cancer Res. 2015 Jul 15;21(14):3140-8. doi: 10.1158/1078-0432.CCR-14-2023. Epub 2015 Jan 21.

38.

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.

Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, Long GV, Hersey P, Scolyer RA.

Pigment Cell Melanoma Res. 2015 May;28(3):245-53. doi: 10.1111/pcmr.12340. Epub 2014 Dec 22.

PMID:
25477049
39.

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward NK, Johansson P, Scolyer RA, Kefford RF, Rizos H.

Nat Commun. 2014 Dec 2;5:5694. doi: 10.1038/ncomms6694.

PMID:
25452114
40.

Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma.

Chan MM, Kefford RF, Carlino M, Clements A, Manolios N.

J Immunother. 2015 Jan;38(1):37-9. doi: 10.1097/CJI.0000000000000060.

PMID:
25415286
41.

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.

Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A.

Ann Oncol. 2015 Feb;26(2):415-21. doi: 10.1093/annonc/mdu529. Epub 2014 Nov 18.

PMID:
25411413
42.

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

Carlino MS, Fung C, Shahheydari H, Todd JR, Boyd SC, Irvine M, Nagrial AM, Scolyer RA, Kefford RF, Long GV, Rizos H.

Clin Cancer Res. 2015 Jan 1;21(1):98-105. doi: 10.1158/1078-0432.CCR-14-0759. Epub 2014 Nov 4.

43.

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R.

J Clin Oncol. 2014 Nov 20;32(33):3697-704. doi: 10.1200/JCO.2014.57.3535. Epub 2014 Oct 6.

44.

Reply to M. Perier-Muzet et al.

Zimmer L, Haydu LE, Menzies AM, Scolyer RA, Kefford RF, Thompson JF, Schadendorf D, Long GV.

J Clin Oncol. 2014 Oct 1;32(28):3203. doi: 10.1200/JCO.2014.56.8477. Epub 2014 Sep 2. No abstract available.

PMID:
25185100
45.

Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.

Lee CI, Menzies AM, Haydu LE, Azer M, Clements A, Kefford RF, Long GV.

Melanoma Res. 2014 Oct;24(5):468-74. doi: 10.1097/CMR.0000000000000110.

PMID:
25054915
46.

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

Chan MM, Haydu LE, Menzies AM, Azer MW, Klein O, Lyle M, Clements A, Guminski A, Kefford RF, Long GV.

Cancer. 2014 Oct 15;120(20):3142-53. doi: 10.1002/cncr.28851. Epub 2014 Jul 1.

47.

Identification of a melanoma susceptibility locus and somatic mutation in TET2.

Song F, Amos CI, Lee JE, Lian CG, Fang S, Liu H, MacGregor S, Iles MM, Law MH, Lindeman NI, Montgomery GW, Duffy DL, Cust AE, Jenkins MA, Whiteman DC, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Brown KM, Martin NG, Mann GJ, Bishop DT, Bishop JA; GenoMEL consortium, Kraft P, Qureshi AA, Kanetsky PA, Hayward NK, Hunter DJ, Wei Q, Han J.

Carcinogenesis. 2014 Sep;35(9):2097-101. doi: 10.1093/carcin/bgu140. Epub 2014 Jun 30.

48.

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, Chin MT, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF.

Clin Cancer Res. 2014 Sep 1;20(17):4449-58. doi: 10.1158/1078-0432.CCR-14-0887. Epub 2014 Jun 23.

49.

Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.

Uribe P, Anforth RM, Kefford RF, Fernandez-Peñas P.

Melanoma Res. 2014 Oct;24(5):501-3. doi: 10.1097/CMR.0000000000000096.

PMID:
24922191
50.

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'Toole SA, Scolyer RA, Long GV.

Br J Cancer. 2014 Jul 15;111(2):292-9. doi: 10.1038/bjc.2014.287. Epub 2014 Jun 10.

Supplemental Content

Loading ...
Support Center